ME00591A - Use of dii4 antagonists in ishemic injury or vascular insufficiency - Google Patents
Use of dii4 antagonists in ishemic injury or vascular insufficiencyInfo
- Publication number
- ME00591A ME00591A MEP-31/09A MEP3109A ME00591A ME 00591 A ME00591 A ME 00591A ME P3109 A MEP3109 A ME P3109A ME 00591 A ME00591 A ME 00591A
- Authority
- ME
- Montenegro
- Prior art keywords
- ischemic
- dii4
- nopati
- reti
- occlusion
- Prior art date
Links
- 206010054880 Vascular insufficiency Diseases 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 208000023577 vascular insufficiency disease Diseases 0.000 title 1
- 230000000302 ischemic effect Effects 0.000 abstract 4
- 108700041286 delta Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 238000002054 transplantation Methods 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 abstract 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 abstract 1
- 206010055665 Corneal neovascularisation Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 102000005650 Notch Receptors Human genes 0.000 abstract 1
- 108010070047 Notch Receptors Proteins 0.000 abstract 1
- 206010035138 Placental insufficiency Diseases 0.000 abstract 1
- 208000005107 Premature Birth Diseases 0.000 abstract 1
- 206010036590 Premature baby Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000005744 arteriovenous malformation Effects 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 201000000159 corneal neovascularization Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000037906 ischaemic injury Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 210000001927 retinal artery Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 208000037905 systemic hypertension Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83600306P | 2006-08-07 | 2006-08-07 | |
| PCT/US2007/017546 WO2008019144A2 (fr) | 2006-08-07 | 2007-08-07 | Procédés thérapeuthiques pour traiter des troubles vasculaires de l'oeil par des antagonistes de dll4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ME00591B ME00591B (fr) | 2011-12-20 |
| ME00591A true ME00591A (en) | 2011-12-20 |
Family
ID=38904599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-31/09A ME00591A (en) | 2006-08-07 | 2007-08-07 | Use of dii4 antagonists in ishemic injury or vascular insufficiency |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20080181893A1 (fr) |
| EP (1) | EP2054082B1 (fr) |
| JP (1) | JP5529536B2 (fr) |
| KR (1) | KR101497355B1 (fr) |
| CN (1) | CN101500605B (fr) |
| AU (1) | AU2007281916B2 (fr) |
| BR (1) | BRPI0716424B8 (fr) |
| CA (1) | CA2660235C (fr) |
| CO (1) | CO6150190A2 (fr) |
| CR (1) | CR10627A (fr) |
| DK (1) | DK2054082T3 (fr) |
| ES (1) | ES2398253T3 (fr) |
| GT (1) | GT200900029A (fr) |
| HR (1) | HRP20130271T1 (fr) |
| IL (1) | IL196612A (fr) |
| MA (1) | MA30667B1 (fr) |
| ME (1) | ME00591A (fr) |
| MX (1) | MX2009000674A (fr) |
| MY (1) | MY150092A (fr) |
| NO (1) | NO341857B1 (fr) |
| NZ (1) | NZ574794A (fr) |
| PL (1) | PL2054082T3 (fr) |
| PT (1) | PT2054082E (fr) |
| RS (1) | RS52685B (fr) |
| RU (1) | RU2429876C2 (fr) |
| SG (1) | SG174033A1 (fr) |
| SI (1) | SI2054082T1 (fr) |
| SV (1) | SV2009003161A (fr) |
| TN (1) | TN2009000036A1 (fr) |
| UA (1) | UA95304C2 (fr) |
| WO (1) | WO2008019144A2 (fr) |
| ZA (1) | ZA200900337B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| WO2008091222A1 (fr) * | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Inhibiteurs de la signalisation dll4 et utilisations associees |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| KR20110051245A (ko) * | 2008-09-10 | 2011-05-17 | 제넨테크, 인크. | 안구 혈관신생의 억제 방법 |
| AU2009294415B2 (en) | 2008-09-19 | 2015-09-24 | Medimmune Llc | Antibodies directed to DLL4 and uses thereof |
| CA2742968C (fr) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Bibliotheques combinatoires d'anticorps et leurs utilisations |
| WO2011008641A1 (fr) | 2009-07-13 | 2011-01-20 | Beth Israel Deaconess Medical Center, Inc. | Méthodes de modulation de langiogenèse et traitement de maladies associées à langiogenèse |
| EP2470568A2 (fr) | 2009-08-29 | 2012-07-04 | Abbott Laboratories | Protéines thérapeutiques se liant à dll4 |
| UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| PL2488204T3 (pl) * | 2009-10-16 | 2016-10-31 | Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych | |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| EP3072904A1 (fr) * | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Protéines de liaison dll4 thérapeutiques |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| DK3485903T5 (da) | 2011-09-23 | 2024-09-02 | Mereo Biopharma 5 Inc | Vegf/dll4-bindende midler og anvendelser deraf |
| WO2014062659A2 (fr) * | 2012-10-15 | 2014-04-24 | Oncomed Pharmaceuticals, Inc. | Méthodes de traitement de maladies oculaires |
| AU2013337811A1 (en) | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| US9931199B2 (en) * | 2014-05-05 | 2018-04-03 | Roberto Gustavo ALBERTAZZI | Methods and apparatus for treating keratoconus |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| WO2018094267A1 (fr) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Nouveaux procédés pour améliorer la prise de greffe microvasculaire de tissus biotechniques et primaires |
| EP4417619A4 (fr) | 2021-10-12 | 2025-12-03 | Palmira Biopharma Llc | Séquence nucléotidique codant une protéine de fusion |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7306799B2 (en) * | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US20060134121A1 (en) * | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| EP1928486A2 (fr) | 2005-09-01 | 2008-06-11 | Vasgene Therapeutics, Inc. | Methodes d'utilisation et d'identification de modulateurs de delta-like 4 |
| CA2654304A1 (fr) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions et procedes destines a moduler le developpement vasculaire |
-
2007
- 2007-08-07 CN CN200780029497.8A patent/CN101500605B/zh active Active
- 2007-08-07 ME MEP-31/09A patent/ME00591A/xx unknown
- 2007-08-07 MX MX2009000674A patent/MX2009000674A/es active IP Right Grant
- 2007-08-07 UA UAA200902033A patent/UA95304C2/ru unknown
- 2007-08-07 WO PCT/US2007/017546 patent/WO2008019144A2/fr not_active Ceased
- 2007-08-07 SG SG2011055829A patent/SG174033A1/en unknown
- 2007-08-07 RS RS20130078A patent/RS52685B/sr unknown
- 2007-08-07 PL PL07811137T patent/PL2054082T3/pl unknown
- 2007-08-07 AU AU2007281916A patent/AU2007281916B2/en active Active
- 2007-08-07 CA CA2660235A patent/CA2660235C/fr active Active
- 2007-08-07 RU RU2009107921/15A patent/RU2429876C2/ru active
- 2007-08-07 US US11/890,741 patent/US20080181893A1/en not_active Abandoned
- 2007-08-07 BR BRPI0716424A patent/BRPI0716424B8/pt active IP Right Grant
- 2007-08-07 SI SI200731170T patent/SI2054082T1/sl unknown
- 2007-08-07 JP JP2009523820A patent/JP5529536B2/ja active Active
- 2007-08-07 PT PT78111374T patent/PT2054082E/pt unknown
- 2007-08-07 NZ NZ574794A patent/NZ574794A/en unknown
- 2007-08-07 HR HRP20130271TT patent/HRP20130271T1/hr unknown
- 2007-08-07 EP EP07811137A patent/EP2054082B1/fr active Active
- 2007-08-07 ES ES07811137T patent/ES2398253T3/es active Active
- 2007-08-07 MY MYPI20090335A patent/MY150092A/en unknown
- 2007-08-07 DK DK07811137.4T patent/DK2054082T3/da active
- 2007-08-07 KR KR1020097004668A patent/KR101497355B1/ko active Active
-
2009
- 2009-01-15 ZA ZA2009/00337A patent/ZA200900337B/en unknown
- 2009-01-20 IL IL196612A patent/IL196612A/en active IP Right Grant
- 2009-02-03 TN TN2009000036A patent/TN2009000036A1/fr unknown
- 2009-02-05 SV SV2009003161A patent/SV2009003161A/es unknown
- 2009-02-06 GT GT200900029A patent/GT200900029A/es unknown
- 2009-02-20 CR CR10627A patent/CR10627A/es unknown
- 2009-02-26 MA MA31667A patent/MA30667B1/fr unknown
- 2009-03-04 NO NO20090984A patent/NO341857B1/no unknown
- 2009-03-05 CO CO09022898A patent/CO6150190A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00591A (en) | Use of dii4 antagonists in ishemic injury or vascular insufficiency | |
| Bentov et al. | The effect of aging on the cutaneous microvasculature | |
| Bae et al. | Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial | |
| JP2015528454A5 (fr) | ||
| US20190381090A1 (en) | Use of dextran sulfate | |
| FI2765988T3 (fi) | Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus | |
| JP2015523986A5 (fr) | ||
| Chang et al. | Corneal penetration by tarantula hairs | |
| RU2575966C2 (ru) | Способ лечения неоваскулярной глаукомы | |
| CY1113840T1 (el) | Χρηση ανταγωνιστων d114 σε ισχαιμικη βλαβη ή αγγειακη ανεπαρκεια | |
| Kalina et al. | Proliferative retinopathy after treatment of carotid-cavernous fistulas | |
| Uva et al. | The effect of timolol-dorzolamide and timolol-pilocarpine combinations on ocular blood flow in patients with glaucoma | |
| Kayikcioglu et al. | Miliary microemboli of the retinal arterioles and choriocapillaris after subcutaneous injection of triamcinolone acetonide | |
| DOP2009000015A (es) | Uso de antagonistas de dll4 para tratar trastornos oculares vasculares | |
| CN107648236B (zh) | 一种预防或治疗缺血/再灌注损伤的药物组合物及应用 | |
| Dalal et al. | Hypothermia as a Neuroprotectant for Neurorehabilitation Eligible Patients: State of the Art Review and Update | |
| BRPI0608272A2 (pt) | método para promover revascularização fisiológica benéfica de tecido retinal isquêmico e método de triagem para identificar e avaliar a eficácia terapêutica de agentes terapêuticos potenciais para tratar doenças neovasculares retinais | |
| RU2306957C1 (ru) | Способ регионарной анестезии при операции ампутации нижних конечностей | |
| RU2607356C2 (ru) | Способ лечения острых нарушений кровообращения сетчатки и зрительного нерва | |
| Omileke et al. | Elucidating the Mechanisms Involved in Intracranial Pressure Elevation and Hypothermia Treatment for Ischaemic Stroke | |
| Niu et al. | Acute visual loss in an orbital arteriovenous malformation | |
| Mateshuk-Vatseba et al. | Morphometric study of angioarchitectonic under the effect of opioid (experimental study) | |
| Neovascularization | What Is New in Ophthalmic Research | |
| Zhang et al. | Observation on the effect of Salvia miltiorrhiza injection in treating traumatic hyphema and the opportune time for its application | |
| Harris et al. | Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics |